Dosage Protocols
Clinical trials employed structured dose-escalation protocols to manage gastrointestinal tolerability:
Starting dose: 0.5 mg weekly (the lowest dose used in Phase 2 dose-ranging)
Escalation schedule: Dose increases every 4 weeks, with slower escalation (6–8 weeks per step) recommended for those experiencing GI side effects. A conservative escalation path: 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg.
Maintenance doses studied:
- 1 mg weekly (low-dose arm in Phase 2, produced -8.7% body weight loss at 48 weeks)
- 4 mg weekly (moderate dose, Phase 2, produced -17.1% weight loss)
- 8 mg weekly (Phase 2)
- 9 mg weekly (Phase 3 TRIUMPH trials)
- 12 mg weekly (maximum studied dose)
Phase 3 titration protocol (TRIUMPH program): The standardized Phase 3 escalation follows 4-week steps: 2 mg → 4 mg → 6 mg → 8 mg → 10 mg → 12 mg, reaching the maximum dose by week 20. Steady state plasma concentrations are reached in 4-5 weeks at each dose level, supporting the 4-week step intervals.
Research indicates that even the 1 mg arm produced clinically meaningful weight loss (-8.7% at 48 weeks), and starting at the lowest available dose with gradual escalation significantly mitigates gastrointestinal adverse events. Higher doses should only be pursued if lower doses prove insufficient after adequate trial periods.
No FDA-approved dosing guidelines exist for retatrutide as of 2026. All protocols referenced are derived from clinical trial data.
Research reconstitution: For research preparations, reconstitution conventions vary. Adding 2 mL of bacteriostatic water to a 10 mg vial yields 5 mg/mL (suitable for smaller injection volumes), while 10 mL yields 1 mg/mL (easier dose calculation). Neither is derived from official guidelines, as no commercial formulation exists.